Importer of Controlled Substances; Notice of Application, 45780-45781 [E8-18045]

Download as PDF 45780 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices in a previous notice published in the Federal Register on September 23, 1975 (40 FR 43745), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17976 Filed 8–4–08; 8:45 am] BILLING CODE 4410–09–P Dated: July 29, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–17977 Filed 8–4–08; 8:45 am] DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on PROD1PC66 with NOTICES Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on June 2, 2008, Wildlife Laboratories, 1401 Duff Drive, Suite 400, Fort Collins, Colorado 80524, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Etorphine Hydrochloride (9059), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance for sale to its customers. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such written comments or objections should be addressed, in quintuplicate, to the Drug Enforcement VerDate Aug<31>2005 16:46 Aug 05, 2008 Jkt 214001 Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, Virginia 22152; and must be filed no later than September 5, 2008. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substance listed in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a), 21 U.S.C. 823(a), and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on March 26, 2008, BA Research International LLC, 10550 Rockley Road, Suite 150, Houston, Texas 77099–0000, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule 4-Methylaminorex (cis isomer) (1590). Gamma Hydroxybutyric Acid (2010). Methaqualone (2565) .................... Ibogaine (7260) ............................. PO 00000 Frm 00088 Fmt 4703 Sfmt 4703 I I I I Drug Lysergic acid diethylamide (7315) Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ...... Cannabidiol (7372) ....................... Mescaline (7381) .......................... 4-Methyl-2,5-dimethoxyamphetamine (7395). 3,4-Methylenedioxyamphetamine (7400). 3,4-Methylenedioxymethamphetamine (7405). Peyote (7415) ............................... Bufotenine (7433) ......................... Diethyltryptamine (7434) ............... Dimethyltryptamine (7435) ............ Psilocybin (7437) .......................... Etorphine (except HCL) (9056) .... Heroin (9200) ................................ Normorphine (9313) ...................... Alphacetylmethadol except levoalphacetylmethadol (9603). Amphetamine (1100) .................... Methamphetamine (1105) ............. Methylphenidate (1724) ................ Amobarbital (2125) ....................... Pentobarbital (2270) ..................... Secobarbital (2315) ...................... Phencyclidine (7471) .................... Cocaine (9041) ............................. Codeine (9050) ............................. Diprenorphine (9058) .................... Etorphine HCL (9059) ................... Oxycodone (9143) ........................ Hydromorphone (9150) ................. Diphenoxylate (9170) .................... Ethylmorphine (9190) ................... Levorphanol (9220) ....................... Dextropropoxyphene, bulk (nondosage forms) (9273). Thebaine (9333) ........................... Opium, raw (9600) ........................ Opium, powdered (9639) .............. Levo-alphacetylmethadol (9648) .. Oxymorphone (9652) .................... Fentanyl (9801) ............................. Hydrocodone (9193) ..................... Meperidine (9230) ......................... Methadone (9250) ........................ Morphine (9300) ........................... Schedule I I I I I I I I I I I I I I I I I II II II II II II II II II II II II II II II II II II II II II II II II II II II The company plans to import analytical reference standards for analytical testing of blood samples from clinical trials. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic classes of controlled substances may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, E:\FR\FM\06AUN1.SGM 06AUN1 45781 Federal Register / Vol. 73, No. 152 / Wednesday, August 6, 2008 / Notices Springfield, Virginia 22152; and must be filed no later than September 5, 2008. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18045 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE Drug Enforcement Administration mstockstill on PROD1PC66 with NOTICES Importer of Controlled Substances; Notice of Application Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to issuing a registration under this Section to a bulk manufacturer of a controlled substance in schedule I or II, and prior to issuing a regulation under 21 U.S.C. 952(a)(2) authorizing the importation of such a substance, provide manufacturers holding registrations for the bulk manufacture of the substance an opportunity for a hearing. Therefore, in accordance with Title 21 Code of Federal Regulations (CFR), 1301.34(a), this is notice that on June 5, 2008, Boehringer Ingelheim Chemicals, Inc., 2820 N. Normandy Drive, Petersburg, Virginia 23805, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of Phenylacetone (8501), a basic class of controlled substance listed in schedule II. The company plans to import the listed controlled substance to bulk manufacture amphetamine. Any bulk manufacturer who is presently, or is applying to be, registered with DEA to manufacture such basic class of controlled substance may file comments or objections to the issuance of the proposed registration and may, at the same time, file a written VerDate Aug<31>2005 16:46 Aug 05, 2008 Jkt 214001 request for a hearing on such application pursuant to 21 CFR 1301.43 and in such form as prescribed by 21 CFR 1316.47. Any such comments or objections should be addressed, in quintuplicate, to the Drug Enforcement Administration, Office of Diversion Control, Federal Register Representative (ODL), 8701 Morrissette Drive, Springfield, VA. 22152; and must be filed no later than September 5, 2008. This procedure is to be conducted simultaneously with, and independent of, the procedures described in 21 CFR 1301.34(b), (c), (d), (e), and (f). As noted in a previous notice published in the Federal Register on September 23, 1975, (40 FR 43745), all applicants for registration to import a basic class of any controlled substance in schedule I or II are, and will continue to be, required to demonstrate to the Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration, that the requirements for such registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 1301.34(b), (c), (d), (e), and (f) are satisfied. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18055 Filed 8–5–08; 8:45 am] manufacture of diagnostic products for distribution to its customers. No comments or objections have been received. DEA has considered the factors in 21 U.S.C. 823(a) and 952(a) and determined that the registration of Roche Diagnostics Operations, Inc. to import the basic classes of controlled substances is consistent with the public interest, and with United States obligations under international treaties, conventions, or protocols in effect on May 1, 1971, at this time. DEA has investigated Roche Diagnostics Operations, Inc. to ensure that the company’s registration is consistent with the public interest. The investigation has included inspection and testing of the company’s physical security systems, verification of the company’s compliance with state and local laws, and a review of the company’s background and history. Therefore, pursuant to 21 U.S.C. 952(a) and § 958(a), and in accordance with 21 CFR 1301.34, the above named company is granted registration as an importer of the basic classes of controlled substances listed. Dated: July 30, 2008. Joseph T. Rannazzisi, Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration. [FR Doc. E8–18064 Filed 8–5–08; 8:45 am] BILLING CODE 4410–09–P BILLING CODE 4410–09–P DEPARTMENT OF JUSTICE DEPARTMENT OF JUSTICE Drug Enforcement Administration Drug Enforcement Administration Importer of Controlled Substances; Notice of Registration By Notice dated March 10, 2008 and published in the Federal Register on March 19, 2008, (73 FR 14839), Roche Diagnostics Operations, Inc., Attn: Regulatory Compliance, 9115 Hague Road, Indianapolis, Indiana 46250, made application by renewal to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Drug Schedule Lysergic acid diethylamide (7315) Alphamethadol (9605) .................. Tetrahydrocannabinols (7370) ..... Cocaine (9041) ............................. Ecgonine (9180) ........................... Methadone (9250) ........................ Morphine (9300) ........................... I I I II II II II The company plans to import the listed controlled substances for the PO 00000 Frm 00089 Fmt 4703 Sfmt 4703 Importer of Controlled Substances; Notice of Registration By Notice dated February 12, 2008 and published in the Federal Register on February 21, 2008, (73 FR 9591), United States Pharmacopeial Convention, 12601 Twinbrook Parkway, Rockville, Maryland 20852, made application to the Drug Enforcement Administration (DEA) to be registered as an importer of the basic classes of controlled substances listed in schedules I and II: Drug Cathinone (1235) .......................... Methaqualone (2565) .................... Lysergic acid diethylamide (7315) Marihuana (7360) ......................... Tetrahydrocannabinols (7370) ...... 4-Methyl-2,5dimethoxyamphetamine (7395). 3,4-Methylenedioxyamphetamine (7400). Codeine-n-oxide (9053) ................ Heroin (9200) ................................ Amphetamine (1100) .................... E:\FR\FM\06AUN1.SGM 06AUN1 Schedule I I I I I I I I I II

Agencies

[Federal Register Volume 73, Number 152 (Wednesday, August 6, 2008)]
[Notices]
[Pages 45780-45781]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: E8-18045]


-----------------------------------------------------------------------

DEPARTMENT OF JUSTICE

Drug Enforcement Administration


Importer of Controlled Substances; Notice of Application

    Pursuant to 21 U.S.C. 958(i), the Attorney General shall, prior to 
issuing a registration under this section to a bulk manufacturer of a 
controlled substance in schedule I or II, and prior to issuing a 
regulation under 21 U.S.C. 952(a)(2) authorizing the importation of 
such a substance, provide manufacturers holding registrations for the 
bulk manufacture of the substance an opportunity for a hearing.
    Therefore, in accordance with Title 21 Code of Federal Regulations 
(CFR), 1301.34(a), this is notice that on March 26, 2008, BA Research 
International LLC, 10550 Rockley Road, Suite 150, Houston, Texas 77099-
0000, made application to the Drug Enforcement Administration (DEA) to 
be registered as an importer of the basic classes of controlled 
substances listed in schedules I and II:

------------------------------------------------------------------------
                    Drug                               Schedule
------------------------------------------------------------------------
4-Methylaminorex (cis isomer) (1590)........  I
Gamma Hydroxybutyric Acid (2010)............  I
Methaqualone (2565).........................  I
Ibogaine (7260).............................  I
Lysergic acid diethylamide (7315)...........  I
Marihuana (7360)............................  I
Tetrahydrocannabinols (7370)................  I
Cannabidiol (7372)..........................  I
Mescaline (7381)............................  I
4-Methyl-2,5-dimethoxyamphet- amine (7395)..  I
3,4-Methylenedioxyamphetamine (7400)........  I
3,4-Methylenedioxymethamphet- amine (7405)..  I
Peyote (7415)...............................  I
Bufotenine (7433)...........................  I
Diethyltryptamine (7434)....................  I
Dimethyltryptamine (7435)...................  I
Psilocybin (7437)...........................  I
Etorphine (except HCL) (9056)...............  I
Heroin (9200)...............................  I
Normorphine (9313)..........................  I
Alphacetylmethadol except levo-               I
 alphacetylmethadol (9603).
Amphetamine (1100)..........................  II
Methamphetamine (1105)......................  II
Methylphenidate (1724)......................  II
Amobarbital (2125)..........................  II
Pentobarbital (2270)........................  II
Secobarbital (2315).........................  II
Phencyclidine (7471)........................  II
Cocaine (9041)..............................  II
Codeine (9050)..............................  II
Diprenorphine (9058)........................  II
Etorphine HCL (9059)........................  II
Oxycodone (9143)............................  II
Hydromorphone (9150)........................  II
Diphenoxylate (9170)........................  II
Ethylmorphine (9190)........................  II
Levorphanol (9220)..........................  II
Dextropropoxyphene, bulk (non-dosage forms)   II
 (9273).
Thebaine (9333).............................  II
Opium, raw (9600)...........................  II
Opium, powdered (9639)......................  II
Levo-alphacetylmethadol (9648)..............  II
Oxymorphone (9652)..........................  II
Fentanyl (9801).............................  II
Hydrocodone (9193)..........................  II
Meperidine (9230)...........................  II
Methadone (9250)............................  II
Morphine (9300).............................  II
------------------------------------------------------------------------

    The company plans to import analytical reference standards for 
analytical testing of blood samples from clinical trials.
    Any bulk manufacturer who is presently, or is applying to be, 
registered with DEA to manufacture such basic classes of controlled 
substances may file comments or objections to the issuance of the 
proposed registration and may, at the same time, file a written request 
for a hearing on such application pursuant to 21 CFR 1301.43 and in 
such form as prescribed by 21 CFR 1316.47.
    Any such comments or objections should be addressed, in 
quintuplicate, to the Drug Enforcement Administration, Office of 
Diversion Control, Federal Register Representative (ODL), 8701 
Morrissette Drive,

[[Page 45781]]

Springfield, Virginia 22152; and must be filed no later than September 
5, 2008.
    This procedure is to be conducted simultaneously with, and 
independent of, the procedures described in 21 CFR 1301.34(b), (c), 
(d), (e), and (f). As noted in a previous notice published in the 
Federal Register on September 23, 1975, (40 FR 43745), all applicants 
for registration to import a basic class of any controlled substance in 
schedule I or II are, and will continue to be, required to demonstrate 
to the Deputy Assistant Administrator, Office of Diversion Control, 
Drug Enforcement Administration, that the requirements for such 
registration pursuant to 21 U.S.C. 958(a); 21 U.S.C. 823(a); and 21 CFR 
1301.34(b), (c), (d), (e), and (f) are satisfied.

    Dated: July 30, 2008.
Joseph T. Rannazzisi,
Deputy Assistant Administrator, Office of Diversion Control, Drug 
Enforcement Administration.
[FR Doc. E8-18045 Filed 8-5-08; 8:45 am]
BILLING CODE 4410-09-P

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.